SLC5A2 and type 2 diabetes mellitus: This meta‐analysis, using a consistent endpoint, supports the robustness of the finding of reduced kidney disease progression across the class of SGLT2 inhibitors in patients with type 2 diabetes either with established ASCVD or at high cardiovascular risk.